Any rhyme or reason as to why you value Zantrene at ~$200m?
The typical response I hear is "one drug, one opportunity and Phase 1". They don't consider the multiple clinically validated drug synergies over the years (not to mention single agent validation) nor the surprising lack of cardiotoxicity demonstrated at Sheba 2.0 (and historically) to be of any real value at all, bizarrely IMO.
General Comments / Chat, page-11096
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.80 |
Change
0.050(2.86%) |
Mkt cap ! $303.1M | |||
| Open | High | Low | Value | Volume |
| $1.82 | $1.82 | $1.77 | $86.48K | 48.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1671 | $1.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.81 | 249 | 1 |
View Market Depth
| Last trade - 15.10pm 10/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |